SubHero Banner

Ibrance® (palbociclib) – Expanded indication, label update

March 31, 2017 – Pfizer announced the FDA approval of Ibrance (palbociclib) for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor (AI) as initial endocrine based therapy in postmenopausal women.

Download PDF